The deal size was reduced to $150M in common stock from $200M in common stock. Goldman Sachs, Leerink, Evercore ISI and Barclays acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- TheStreet Pro: Four Stocks that Will Win Despite “Irrational Panic” over AI
- Vir Biotechnology’s Call Highlights Astellas Deal, VIR-5500 Momentum
- Vir Biotechnology announces $200M public offering of common stock
- Vir Biotechnology price target raised to $30 from $26 at Barclays
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories on Feb. 24